GlassScriptPhysician profile
Diana Jimenez
NPI 1144932971
$2,489.22
in general payments reported to CMS, 2019-2025
20 companies · $748 in 2025
The $748 reported for 2025 was more than what 78% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $894 · 2024: $846 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,489.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,489.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $421.03 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $294.91 | 2023-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $287.00 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $223.88 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $193.01 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $176.79 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $173.13 | 2023 | |
| Abbvie INC. | $159.12 | 2023-2025 | |
| Abbott Laboratories | $101.19 | 2023-2025 | Freestyle Libre |
| Dexcom, INC. | $88.71 | 2024-2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $87.16 | 2023-2025 | Shingrix, Arexvy |
| Almatica Pharma LLC | $79.28 | 2023-2024 | Loreev Xr, Sertraline Hcl |
| Sumitomo Pharma America, INC. | $57.31 | 2023-2024 | Gemtesa |
| Corium, LLC | $26.46 | 2023 | Adlarity |
| Ibsa Pharma INC. | $23.88 | 2025 | Flector, Tirosint, Licart |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $23.72 | 2023 | Quviviq |
| Sanofi-Aventis U.S. LLC | $19.53 | 2023 | |
| Phathom Pharmaceuticals, INC. | $18.89 | 2024 | Voquezna |
| Phadia US INC. | $18.78 | 2023 | Immunocap |
| Novartis Pharmaceuticals Corporation | $15.44 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.